238 related articles for article (PubMed ID: 21815183)
1. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease.
Brandow AM; Panepinto JA
Am J Hematol; 2011 Sep; 86(9):804-6. PubMed ID: 21815183
[TBL] [Abstract][Full Text] [Related]
2. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.
Aygun B; Mortier NA; Smeltzer MP; Shulkin BL; Hankins JS; Ware RE
Am J Hematol; 2013 Feb; 88(2):116-9. PubMed ID: 23255310
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
5. Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.
Mvalo T; Topazian H; Kamthunzi P; Chen J; Kambalame I; Mafunga P; Mumba N; Chiume-Chiphaliwali M; Paseli K; Key N; Gopal S; Hoffman I; Ataga K; Westmoreland K
Blood Adv; 2018 Nov; 2(Suppl 1):30-32. PubMed ID: 30504195
[No Abstract] [Full Text] [Related]
6. Hydroxycarbamide for sickle-cell anaemia in infancy.
Weatherall DJ
Lancet; 2011 May; 377(9778):1628-30. PubMed ID: 21571132
[No Abstract] [Full Text] [Related]
7. Hydroxyurea in children with sickle cell disease in a resource-poor setting: Monitoring and effects of therapy. A practical perspective.
Nnebe-Agumadu U; Adebayo I; Erigbuem I; James E; Kumode E; Nnodu O; Adekile A
Pediatr Blood Cancer; 2021 Jun; 68(6):e28969. PubMed ID: 33788390
[TBL] [Abstract][Full Text] [Related]
8. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
Zimmerman SA; Schultz WH; Davis JS; Pickens CV; Mortier NA; Howard TA; Ware RE
Blood; 2004 Mar; 103(6):2039-45. PubMed ID: 14630791
[TBL] [Abstract][Full Text] [Related]
9. Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria.
Adeyemo TA; Diaku-Akinwunmi IN; Ojewunmi OO; Bolarinwa AB; Adekile AD
Hemoglobin; 2019 May; 43(3):188-192. PubMed ID: 31462098
[TBL] [Abstract][Full Text] [Related]
10. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
Quinn CT; Niss O; Dong M; Pfeiffer A; Korpik J; Reynaud M; Bonar H; Kalfa TA; Smart LR; Malik P; Ware RE; Vinks AA; McGann PT
Br J Haematol; 2021 Aug; 194(3):617-625. PubMed ID: 34227124
[TBL] [Abstract][Full Text] [Related]
11. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
[TBL] [Abstract][Full Text] [Related]
12. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
[TBL] [Abstract][Full Text] [Related]
13. Adherence to hydroxyurea therapy in children with sickle cell anemia.
Thornburg CD; Calatroni A; Telen M; Kemper AR
J Pediatr; 2010 Mar; 156(3):415-9. PubMed ID: 19880135
[TBL] [Abstract][Full Text] [Related]
14. Long-term use of hydroxyurea for sickle cell anemia.
Hagar W
JAMA; 2003 Aug; 290(6):753; author reply 754. PubMed ID: 12915424
[No Abstract] [Full Text] [Related]
15. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
Hoppe C; Vichinsky E; Quirolo K; van Warmerdam J; Allen K; Styles L
J Pediatr Hematol Oncol; 2000; 22(4):330-4. PubMed ID: 10959903
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea therapy for sickle cell anemia.
McGann PT; Ware RE
Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
[TBL] [Abstract][Full Text] [Related]
17. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
18. When should hydroxyurea be used for children with sickle cell disease?
Mueller BU
Pediatrics; 2008 Dec; 122(6):1365-6. PubMed ID: 19047256
[No Abstract] [Full Text] [Related]
19. Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood.
Heitzer AM; Longoria J; Okhomina V; Wang WC; Raches D; Potter B; Jacola LM; Porter J; Schreiber JE; King AA; Kang G; Hankins JS
Br J Haematol; 2021 Oct; 195(2):256-266. PubMed ID: 34272726
[TBL] [Abstract][Full Text] [Related]
20. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL;
Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]